Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pregnancy Label Due Date Approaching? Risk, Clinical Info Could Be Split

Executive Summary

FDA is seeking to move ahead quickly with new regulations for pregnancy labeling following the release of the physician labeling final rule

You may also be interested in...



FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg

FDA's proposed rule to update the format of the pregnancy and lactation sections of drug labeling does not require the firms collect new data about their products, but the agency is hoping to use various mechanisms to encourage them to do so

FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg

FDA's proposed rule to update the format of the pregnancy and lactation sections of drug labeling does not require the firms collect new data about their products, but the agency is hoping to use various mechanisms to encourage them to do so

Early Pregnancy Safety Concerns With ACE Inhibitors Could Affect ARBs

Concerns about exposure to angiotensin-converting enzyme inhibitors during the first trimester of pregnancy could have consequences for other classes of antihypertensives, including angiotensin II receptor blockers

Related Content

UsernamePublicRestriction

Register

PS047163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel